What has NICE said?

What has NICE said?

Abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) are recommended as possible treatments for people with polyarticular juvenile idiopathic arthritis.

Adalimumab and etanercept are recommended as possible treatments for people with enthesitis-related juvenile idiopathic arthritis.

Etanercept is recommended as a possible treatment for people with psoriatic juvenile idiopathic arthritis.

What does this mean?

If your (or your child's) doctor thinks that abatacept, adalimumab, etanercept or tocilizumab are the right treatment, you (or your child) should be able to have the treatment on the NHS.

Abatacept, adalimumab, etanercept and tocilizumab should be available on the NHS within 3 months of the guidance being issued.

If you (or your child) are not eligible for treatment as described above, you (or your child) should be able to continue taking abatacept, adalimumab, etanercept or tocilizumab until you and your (or your child's) doctor decide it is the right time to stop.

  • Information Standard